Purvalanol B

Overview

Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK , with IC 50 s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B , CDK2-cyclin A , CDK2-cyclin E and CDK5-p35 , respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC 50 >1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-18299
• CAS No.: 212844-54-7
• Molecular Formula: C20H25ClN6O3
• Molecular Weight: 432.90
• Purity: 97.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution
• Availability: In-stock

Source

Original product source